March 28, 2022 -- NanoTemper Technologies has launched Spectral Shift technology within their Dianthus instrument, which the company said is built to handle the most challenging affinity-based screenings in drug discovery.
The development will aid in affinity-based screenings and drug discovery, which will alleviate challenges like targeting proteolysis-targeting chimeras, intrinsically disordered proteins, or fragment libraries, the company said.